Economic Outcomes of Colfosceril Palmitate Rescue Therapy in Infants Weighing 1250g or More with Respiratory Distress Syndrome
Authors:
- 1 October 1994
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 6 (4) , 358-369
Abstract
Summary An analysis of the economic data from a l11ulticClltrc, randomised, placebocontrolled clinical trial of colfosccri l palmitate in infants with neonatal respiratory distress syndrome (NRDS) and...Keywords
This publication has 22 references indexed in Scilit:
- Economic consequences of surfactant therapy.1993
- Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant.1992
- Cost implications of different approaches to the prevention of respiratory distress syndrome.Archives of Disease in Childhood, 1991
- Cost-effectiveness of HMG-CoA Reductase Inhibition for Primary and Secondary Prevention of Coronary Heart DiseaseJAMA, 1991
- Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: A multicenter controlled trialThe Journal of Pediatrics, 1991
- Impact of surfactant treatment on cost of neonatal intensive care: a cost-benefit analysis.1990
- Increased survival rate in very low birth weight infants (1500 grams or less): No association with increased incidence of handicapsThe Journal of Pediatrics, 1990
- Surfactant Replacement Therapy: Impact on Hospital Charges for Premature Infants With Respiratory Distress SyndromePediatrics, 1989
- Economic Evaluation of Neonatal Intensive Care of Very-Low-Birth-Weight InfantsNew England Journal of Medicine, 1983
- The Distinction Between Cost and ChargesAnnals of Internal Medicine, 1982